Munich-based biotech Tubulis, a developer of cancer-targeting antibody-drug conjugates (ADCs), has secured €308 million in a Series C round led by Venrock Healthcare Capital Partners, with new investors Wellington Management and Ascenta Capital, alongside participation from existing backers.
- Launched in 2017 by Dr. Dominik Schumacher and Dr. Christian Grøndahl, Tubulis develops antibody-drug conjugates (ADCs) by combining proprietary chemical and protein technologies with disease-specific biology.
- The company generates matched protein-drug conjugates with enhanced biophysical properties that allow durable tumor targeting and sustained anti-tumor activity.
- Tubulis’ platform enables the design and production of ADCs across a range of indications, supporting both its own pipeline, currently led by TUB-040, targeting NaPi2b, and TUB-030, targeting 5T4, and development programs for partners with antibody and chemical assets.
Details of the deal
- The fresh capital came from Venrock Healthcare Capital Partners, Wellington Management, and Ascenta Capital, along with participation from existing investors Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, High-Tech Gründerfonds (HTGF), OCCIDENT, and Seventure Partners.
“The company is now positioned to translate an exceptional preclinical foundation into meaningful clinical results, with several important readouts on the horizon. As Tubulis continues to expand its pipeline and build momentum, I’m excited to partner with the leadership team and Board to advance a new generation of ADC medicines for patients," explains Nimish Shah, Partner at Venrock Healthcare Capital Partners.
- Tubulis will use the new funding to advance its lead ADC candidate TUB-040 into earlier treatment lines and additional tumor types, support the development of other pipeline programs including TUB-030, and expand its proprietary ADC platform to enable novel therapeutic applications.
